Connect with us

Business

For plant-touching marijuana companies, most lending options tied to property

Published

on

When it comes to borrowing money as a marijuana company, most roads lead to real estate.

“The industry has challenges accessing capital markets that other industries do not,” Travis Goad, managing partner at Pelorus Equity Group, said of plant-touching marijuana companies.

“In a fully developed market, there’s real estate as one lending source and then there are pure corporate loans as another lending source. In this space, the vast majority of financing is tied to your real estate,” added Goad, whose firm is a cannabis-focused real estate lender.

Applications for cannabis business licenses often require proof of real estate, leaving precious little capital for successful applicants to get their companies up and running.

For marijuana businesses that own property, there are three main ways to borrow, according to Goad, who runs Pelorus’ New York office:

Real estate lending: These loans require borrowers to contribute 25%-40% in equity. The other 60%-75% of the facility’s cost is returned to the borrower in the form of a mortgage, which can be used for construction and other business purposes.

Sale-leaseback agreements: Some finance companies offering sale-leaseback agreements will purchase a property for 100% of a site’s cost to complete, though financing costs are typically higher than with traditional real estate lending.

Business-development company: Lenders in this category might offer up to 180% of a property’s value. However, the higher proceeds come with stringent corporate covenants, higher costs and often require giving up board seats or other control to the lender.

Lenders are looking for hard assets to back their loans, and few options exist for no-asset lending in the cannabis industry.

Shopping around

Dana Arvidson, chief operating officer of Boston-based Tilt Holdings, said that when his company started looking for options to raise funds, the executive team met with the “main providers in the market.”

Tilt, which provides cannabis technology and hardware as well as cultivation and  manufacturing, let the lenders know that its executives were meeting with other groups, the process was competitive and they were looking for the “most attractive rates and terms possible.”

Tilt ultimately chose Innovative Industrial Properties (IIPR), a San Diego-based real estate investment trust, to fund a $40 million sale-leaseback agreement on a 104,000-square-foot cultivation and manufacturing facility in Taunton, Massachusetts. The first deal closed in May 2022, and the multistate operator expects to close a second sale-leaseback on a cultivation-manufacturing property in White Haven, Pennsylvania, this quarter.

“We had done this calculus leading up to the transaction that we did in May of last year. One option that we explored pretty closely was to finance the property specifically with a mortgage, which can be pretty attractive in some ways, because you can get bank-level interest rates and retain ownership of the property,” Arvidson said.

“The challenge that we found with bank financing is that banks are somewhat limited in how they can value cannabis cultivation properties, given the federal status of cannabis. They don’t have the ability to value the property at quite the same level as a sale-leaseback.

“Given that, for us, the purpose of the (funding) was ultimately to retire long-term debt, it made the most sense for us to enter into a sale-leaseback,” he said.

The Massachusetts sale-leaseback agreement netted Tilt $27 million in proceeds. In exchange, Tilt will lease the facility back from IIPR for 20 years, with the possibility of two, five-year extensions.

Transactions slowing

In early January, Goad said Pelorus was offering construction loans with interest rates in the “mid-teens” and rates for “stabilized loans,” or facilities that are already operational, starting in the low teens.

Paul Smithers, CEO of IIPR, told MJBizMagazine via email that, “We continue to see 15-20-year lease terms and low- to mid- double-digit initial yields, with fixed-rate annual escalations.”

According to New York City-based Viridian Capital Advisors, cannabis capital raises were down 64% from the previous year as of Oct. 28, 2022, with debt financing accounting for more than 95% of all capital raised.

IIPR’s sale-leaseback deals, too, were down more than 75% from the previous year as of Sept. 30, 2022, according to an investor presentation by the REIT.

Smithers said that “all capital providers to the cannabis industry saw a slowdown in 2022 due to various headwinds experienced across the industry: lack of capital availability across the board and ever more stringent underwriting requirements.”

“This is not to say that the demand for capital—and specifically real estate capital—has waned in a material way from prior years, but sale-leaseback deal activity can mirror the broader capital raising/M&A ebbs and flows experienced by the industry in general.”

Al Brooks, head of commercial real estate for banking giant JPMorgan Chase & Co., said in a December 2022 report that he expects “challenges ahead” in 2023.

“Retail is at a crossroads, and the future of office space is unclear. Plus, supply chain issues persist, and inflation is near 40-year highs, prompting the (Federal Reserve) to steadily increase interest rates,” Brooks wrote.

 Weighing the options

Boca Raton, Florida-based multistate operator Jushi Holdings took on a sale-leaseback deal when it acquired Pennsylvania Medical Solutions (PAMS), a grower-processor with operations in Scranton, Pennsylvania, from Vireo Health in 2020.

“When we inherited the business, we inherited the current lease with the current market cap rates and the dollars that have been put toward the building that we are moving into,” said Trent Woloveck, chief strategy director at Jushi.

Woloveck said that Jushi carefully considered the sale-leaseback deal when it was conducting due diligence on the PAMS acquisition, given that Jushi had been able to grow its own business using other funding tools and assuming minimal debt.

“Financing other large capex (capital expenditure) projects … off our own balance sheet … has allowed us flexibility as we continue to move forward and be in a better position to take cheaper debt,” Woloveck said. “The issue with the sale-leaseback is it’s forever.”

While traditional real estate loans often have a clause for early repayment, sale-leaseback agreements are typically for 15-20 years, and refinancing options are few.

Goad, the marijuana lender from Pelorus, posited that “when there’s a legalization event … you don’t get to benefit from that, because you’ve locked in today’s cost of capital, and it goes up every year.”

“When all your competitors may be able to go borrow at 7%, you are stuck paying 12% or 15%,” he said.

That said, the timing of legalization is anyone’s guess.

Smithers, meanwhile, said that the long-term nature of sale-leasebacks provide operators with “long-term control over their mission-critical facilities … without the added risk of near-term maturity dates.”

Doubling down

In the case of Jushi’s Pennsylvania facility, the previous owner entered a 15-year, $8.6 million sale-leaseback deal in 2018. The amount included $2.8 million worth of tenant improvements on the 89,000-square-foot industrial space.

In 2021, after acquiring the property, Jushi expanded its agreement with IIPR for an additional $30 million. At the time, the MSO announced it would use the extra cash to finish building out the facility and expand it by 40,000 square feet.

Vireo’s initial sale-leaseback agreement with IIPR—the largest provider of such deals to the marijuana industry—was for annualized aggregate base rent equal to 15% of the sum of the purchase price and tenant improvements. In addition, rent was subject to annual increases of 3.5% for the term of the lease.

Woloveck said that Jushi has “done subsequent borrows on the property in deals with IIPR, and we’ve been able to negotiate a lower cap rates based on our credit.

“Those have been at different rates than what the original deal was struck at,” he added.

In December, Jushi entered a $2 million sale-leaseback deal with Los Angeles-based XS Financial, a capital financing provider, for heavy equipment such as Auto Cure, which automates the cannabis drying and curing process.

“Things that IIPR wouldn’t give us credit for roll into the principal amount. XS is a backstop from that perspective,” Woloveck said.

Source: https://mjbizdaily.com/for-plant-touching-marijuana-companies-most-lending-options-tied-to-property/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News